查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961109

麻醉剂市场－全球产业规模、份额、趋势、机会、预测：按类型、应用、给药途径、地区和竞争格局划分，2021-2031年

Anesthesia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球麻醉剂市场预计将从 2025 年的 39.2 亿美元成长到 2031 年的 62.4 亿美元，复合年增长率为 8.06%。

这些药物对于诱导可逆性感觉和意识丧失至关重要，从而确保诊断和手术操作的安全进行。市场成长趋势主要受全球手术量增加的推动，而手术量的增加又源自于人口老化和需要手术治疗的慢性疾病病例的增加。此外，新兴市场门诊手术中心的普及和医疗基础设施的完善也为持续的需求奠定了坚实的基础，凸显了麻醉药物治疗在现代医学中的关键作用。

市场概览
预测期 2027-2031
市场规模：2025年 39.2亿美元
市场规模：2031年 62.4亿美元
复合年增长率：2026-2031年 8.06%
成长最快的细分市场 全身麻醉剂
最大的市场 北美洲

儘管市场具有成长潜力，但供应链脆弱性和生产不规范等问题仍构成重大障碍。其中一个主要障碍是频繁发生的急性药物短缺，这会扰乱临床工作流程并使治疗安排变得复杂。根据美国医疗保健系统药剂师协会 (ASHP) 的数据，2024 年第一季有效药物短缺事件达到创纪录的 323 起，严重影响了无菌注射和基本麻醉剂的供应。这种不稳定性迫使医疗机构推迟治疗或依赖替代方案，造成市场波动，限制了整体市场的扩张能力。

市场驱动因素

推动全球麻醉剂市场成长的主要因素是全球外科手术数量的增加，这既包括创伤性急性病例，也包括择期手术。随着医疗系统从过去的混乱中恢復，麻醉剂数量显着增加，直接带动了全身麻醉、区域麻醉和局部麻醉剂的消耗。这一趋势在积极开展择期手术以改善患者照护的麻醉剂公共医疗机构中尤为明显。例如，根据英国国家医疗服务体系（NHS England）2025年7月发布的《月度手术统计数据》，仅2025年5月，医疗机构开展的择期手术数量就达到了创纪录的150万例，表明手术活动显着增加，因此需要稳定的麻醉剂供应。

同时，人口老化的快速成长是推动麻醉剂市场发展的根本动力，因为老年人更容易因老龄化相关疾病而需要手术。这种人口结构的变化持续推高了对麻醉剂的需求，尤其是那些适用于合併多种疾病且对镇静剂更为敏感的患者。根据世界卫生组织（世卫组织）于2025年2月发布的最新全球老化数据，2024年出生时的平均寿命将达到73.3岁，凸显了需要医疗干预的老年人群体不断扩大。这为製造商创造了稳定的收入来源。例如，Hikma Pharmaceuticals在其于2025年2月发布的「2024财年财务业绩报告」中指出，其主要麻醉剂供应业务——注射麻醉剂业务的收入在2024年增长了9%，达到13亿美元。

市场挑战

供应链脆弱性和生产不稳定是全球麻醉剂市场成长的主要障碍。这些运作问题经常导致神经肌肉阻断剂和镇痛药等外科手术必需的无菌注射药物供不应求。一旦因品管问题或原材料短缺导致生产中断，医疗机构将面临库存短缺的困境。这种不稳定性会降低麻醉剂药品的整体消耗量，迫使医院推迟择期手术并减少手术室排班，直接阻碍市场成长。

这些供应中断造成的经济影响巨大，供应不稳定削弱了医疗服务提供者的信心，并威胁其收入的可持续性。近期行业数据显示，这一问题持续存在。根据美国系统药剂师协会 (ASHP) 的报告，2024 年约 46% 的新药短缺与注射剂（麻醉剂的主要给药途径）有关。基本製剂频繁短缺会扰乱临床计划，迫使使用效果欠佳的替代品，并最终限制该行业的盈利能力和稳定性。

市场趋势

随着全球医疗系统努力实现临床营运的脱碳，采用永续且环保的麻醉技术正在改变这一领域。医疗机构正在加速从高全球暖化潜势值（GWP）的挥发性气体（如地氟烷）转向低碳替代方案，例如SEVOFLURANE和全静脉麻醉（TIVA）。这项转变旨在透过最大限度地减少空气污染和提高气体供应效率来降低对环境的影响。这种转变的经济效益也日益显现。英国国家医疗服务体系（NHS）于2025年2月发布的《绿色规划指南》指出，设定减少医用气体管道中氧化亚氮废弃物的目标，每年将节省约500万英镑。这表明，环保策略不仅具有环境价值，而且具有经济可行性。

同时，多方面镇痛和减少阿片类药物用量的镇痛方法的广泛应用，刺激了对创新非麻醉性疼痛管理解决方案的需求。为了应对鸦片类药物危机并改善手术效果，医疗机构正在将局部麻醉剂和神经阻断纳入加速復健外科（ERAS）通讯协定。这项策略减少了对全身性鸦片类药物的依赖，从而减少了术后併发症并促进了患者更早出院。这种需求的激增正在对市场消费模式产生重大影响。在2025财年第一季财报（2025年5月）中，Pasila Biosciences公司报告称，其非鸦片类止痛药Exparel在2025年第一季的净销售额达到1.365亿美元。这主要得益于平均每日用量增加了7%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球麻醉剂市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（全身麻醉剂、局部麻醉剂）
    • 依应用领域（一般外科、整形外科、美容外科、牙科手术等）
    • 给药途径（吸入、静脉注射、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美麻醉剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲麻醉剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太麻醉剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲麻醉剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲麻醉剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球麻醉剂市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GSK Plc
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • AstraZeneca Plc
  • Abbott Laboratories Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Eli Lilly and Company

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27578

The Global Anesthesia Drugs Market is projected to expand from a valuation of USD 3.92 billion in 2025 to USD 6.24 billion by 2031, reflecting a compound annual growth rate of 8.06%. These pharmacological agents are essential for inducing reversible loss of sensation or consciousness, enabling safe diagnostic and surgical interventions. The market's upward trajectory is largely underpinned by the rising volume of global surgeries, driven by an aging demographic and a higher prevalence of chronic diseases necessitating operative care. Additionally, the proliferation of ambulatory surgical centers and the development of healthcare infrastructure in emerging markets provide a solid foundation for continued demand, highlighting the critical role of anesthetic pharmacotherapy in contemporary medicine.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.92 Billion
Market Size 2031USD 6.24 Billion
CAGR 2026-20318.06%
Fastest Growing SegmentGeneral Anesthesia Drugs
Largest MarketNorth America

Despite this growth potential, the market faces substantial obstacles stemming from supply chain fragility and manufacturing irregularities. A major impediment is the frequent occurrence of acute medication shortages, which interrupts clinical workflows and complicates scheduling. Data from the American Society of Health-System Pharmacists indicates that in the first quarter of 2024, active drug shortages reached a record high of 323, severely affecting the availability of sterile injectables and vital anesthesia drugs. Such instability compels healthcare providers to postpone procedures or resort to alternatives, creating volatility that restricts the market's overall capacity for expansion.

Market Driver

The primary force accelerating the Global Anesthesia Drugs Market is the escalating number of surgical procedures worldwide, driven by both acute trauma cases and planned interventions. As health systems recover from past disruptions, there has been a notable surge in surgical throughput, which directly fuels the consumption of general, regional, and local anesthetics. This trend is especially pronounced in major public health sectors where backlogs of elective cases are being aggressively managed to enhance patient care. For example, NHS England's 'Monthly operational statistics' from July 2025 reveal that healthcare providers completed a record 1.5 million elective treatments in May 2025 alone, indicating a significant intensification of surgical activity that requires a reliable supply of anesthetics.

In parallel, the rapid growth of the geriatric population acts as a fundamental driver, given that older adults disproportionately require surgery for age-related ailments. This demographic shift sustains demand for anesthetic agents specifically suited for patients with complex comorbidities and heightened sensitivity to sedation. According to the World Health Organization's February 2025 update on global ageing, life expectancy at birth rose to 73.3 years in 2024, highlighting the expanding cohort of elderly individuals needing medical intervention. This creates a consistent revenue stream for manufacturers; notably, Hikma Pharmaceuticals reported in their 'Annual Results 2024' (February 2025) that their Injectables business, a key anesthesia supplier, achieved a 9% revenue increase to $1.3 billion in 2024.

Market Challenge

Supply chain vulnerabilities and inconsistencies in manufacturing represent a significant hurdle to the growth of the Global Anesthesia Drugs Market. These operational failures often lead to shortages of critical sterile injectables, such as neuromuscular blockers and analgesics, which are essential for surgical procedures. When production is halted due to quality control issues or raw material shortages, healthcare facilities face immediate gaps in inventory. This instability directly inhibits market growth by forcing hospitals to delay elective surgeries or curtail operating room schedules, thereby reducing the overall volume of anesthetic product consumption.

The economic repercussions of these disruptions are substantial, as unreliability undermines provider confidence and threatens revenue continuity. The persistence of this problem is highlighted by recent industry data; the American Society of Health-System Pharmacists reported that in 2024, approximately 46% of new drug shortages involved injectable medications, the primary form of anesthesia delivery. This high frequency of deficits in essential formulations disrupts clinical planning and necessitates the use of less ideal alternatives, ultimately limiting the sector's revenue potential and stability.

Market Trends

The adoption of sustainable and green anesthesia practices is transforming the sector as healthcare systems around the world seek to decarbonize clinical operations. Institutions are increasingly moving away from volatile gases with high global warming potential, such as desflurane, in favor of lower-carbon alternatives like sevoflurane or Total Intravenous Anesthesia (TIVA). This shift aims to minimize atmospheric pollution and improve gas delivery efficiency to lessen environmental impact. The financial benefits of this transition are becoming evident; NHS England's 'Green plan guidance' from February 2025 notes that targeting nitrous oxide waste reduction in medical gas pipelines is generating annual savings of approximately £5 million, demonstrating the economic viability of eco-friendly strategies alongside their environmental value.

Concurrently, the increasing use of multimodal and opioid-sparing analgesia is stimulating demand for innovative non-narcotic pain management solutions. To address the opioid crisis and enhance surgical outcomes, providers are incorporating long-acting local anesthetics and nerve blocks into Enhanced Recovery After Surgery (ERAS) protocols. This strategy lessens dependence on systemic opioids, thereby reducing postoperative complications and speeding up patient discharge. This surge in demand is significantly affecting market consumption patterns; Pacira BioSciences reported in their 'First Quarter 2025 Financial Results' (May 2025) that net product sales for their non-opioid analgesic EXPAREL reached $136.5 million in Q1 2025, driven by a 7% increase in average daily volume usage.

Key Market Players

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GSK Plc
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • AstraZeneca Plc
  • Abbott Laboratories Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Eli Lilly and Company

Report Scope

In this report, the Global Anesthesia Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anesthesia Drugs Market, By Type

  • General Anesthesia Drugs
  • Local Anesthesia Drugs

Anesthesia Drugs Market, By Application

  • General Surgery
  • Plastic Surgery
  • Cosmetic Surgery
  • Dental Surgery
  • Others

Anesthesia Drugs Market, By Route of Administration

  • Inhalation
  • Intravenous
  • Others

Anesthesia Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anesthesia Drugs Market.

Available Customizations:

Global Anesthesia Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anesthesia Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (General Anesthesia Drugs, Local Anesthesia Drugs)
    • 5.2.2. By Application (General Surgery, Plastic Surgery, Cosmetic Surgery, Dental Surgery, Others)
    • 5.2.3. By Route of Administration (Inhalation, Intravenous, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Anesthesia Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anesthesia Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Canada Anesthesia Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Mexico Anesthesia Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Route of Administration

7. Europe Anesthesia Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Route of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anesthesia Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. France Anesthesia Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. United Kingdom Anesthesia Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Route of Administration
    • 7.3.4. Italy Anesthesia Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Route of Administration
    • 7.3.5. Spain Anesthesia Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Route of Administration

8. Asia Pacific Anesthesia Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Route of Administration
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anesthesia Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. India Anesthesia Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Japan Anesthesia Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Route of Administration
    • 8.3.4. South Korea Anesthesia Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Route of Administration
    • 8.3.5. Australia Anesthesia Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Anesthesia Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Route of Administration
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anesthesia Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. UAE Anesthesia Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. South Africa Anesthesia Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Route of Administration

10. South America Anesthesia Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Route of Administration
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anesthesia Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Route of Administration
    • 10.3.2. Colombia Anesthesia Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Route of Administration
    • 10.3.3. Argentina Anesthesia Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anesthesia Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. GSK Plc
  • 15.4. Bayer AG
  • 15.5. Dr. Reddy's Laboratories Ltd.
  • 15.6. Viatris Inc.
  • 15.7. AstraZeneca Plc
  • 15.8. Abbott Laboratories Inc.
  • 15.9. Sun Pharmaceutical Industries Ltd.
  • 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer